Journal article
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
- Abstract:
-
This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Korean Association for the Study of Intestinal Diseases Publisher's website
- Journal:
- Intestinal research Journal website
- Volume:
- 14
- Issue:
- 2
- Pages:
- 152-163
- Publication date:
- 2016-04-27
- Acceptance date:
- 2016-03-15
- DOI:
- EISSN:
-
2288-1956
- ISSN:
-
1598-9100
- Source identifiers:
-
623104
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:623104
- UUID:
-
uuid:8a061575-aee5-4587-b991-7eac7c491127
- Local pid:
- pubs:623104
- Deposit date:
- 2016-06-23
Terms of use
- Copyright holder:
- Korean Association for the Study of Intestinal Diseases
- Copyright date:
- 2016
- Notes:
- This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
If you are the owner of this record, you can report an update to it here: Report update to this record